Equities research analysts expect LeMaitre Vascular Inc (NASDAQ:LMAT) to announce sales of $30.49 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for LeMaitre Vascular’s earnings, with the lowest sales estimate coming in at $30.47 million and the highest estimate coming in at $30.51 million. LeMaitre Vascular reported sales of $28.39 million during the same quarter last year, which indicates a positive year over year growth rate of 7.4%. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 18th.
On average, analysts expect that LeMaitre Vascular will report full year sales of $117.57 million for the current year, with estimates ranging from $117.53 million to $117.60 million. For the next year, analysts forecast that the firm will post sales of $129.66 million, with estimates ranging from $128.70 million to $130.25 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Wednesday, October 23rd. The medical instruments supplier reported $0.25 EPS for the quarter, beating the consensus estimate of $0.21 by $0.04. The business had revenue of $29.10 million during the quarter, compared to the consensus estimate of $28.15 million. LeMaitre Vascular had a net margin of 16.76% and a return on equity of 13.38%. The company’s revenue was up 20.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.21 earnings per share.
In related news, CEO George W. Lemaitre sold 4,891 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $35.03, for a total value of $171,331.73. Following the sale, the chief executive officer now owns 3,135,398 shares of the company’s stock, valued at $109,832,991.94. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David B. Roberts sold 12,202 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $35.29, for a total transaction of $430,608.58. Following the completion of the sale, the director now directly owns 35,226 shares in the company, valued at approximately $1,243,125.54. The disclosure for this sale can be found here. Insiders have sold 237,435 shares of company stock valued at $8,408,790 over the last quarter. Company insiders own 19.60% of the company’s stock.
Several institutional investors have recently modified their holdings of LMAT. Russell Investments Group Ltd. grew its stake in shares of LeMaitre Vascular by 92.3% in the third quarter. Russell Investments Group Ltd. now owns 360,859 shares of the medical instruments supplier’s stock worth $12,333,000 after purchasing an additional 173,214 shares during the last quarter. Copeland Capital Management LLC grew its stake in shares of LeMaitre Vascular by 38.7% in the third quarter. Copeland Capital Management LLC now owns 536,199 shares of the medical instruments supplier’s stock worth $18,327,000 after purchasing an additional 149,642 shares during the last quarter. GW&K Investment Management LLC bought a new stake in shares of LeMaitre Vascular in the second quarter worth $3,734,000. Morgan Stanley grew its stake in shares of LeMaitre Vascular by 151.7% in the second quarter. Morgan Stanley now owns 202,672 shares of the medical instruments supplier’s stock worth $5,671,000 after purchasing an additional 122,152 shares during the last quarter. Finally, Nuveen Asset Management LLC bought a new stake in shares of LeMaitre Vascular in the second quarter worth $2,612,000. 79.17% of the stock is currently owned by institutional investors.
Shares of NASDAQ:LMAT opened at $35.37 on Tuesday. The company has a fifty day moving average of $34.63 and a 200-day moving average of $31.34. The company has a market capitalization of $711.09 million, a PE ratio of 42.11, a price-to-earnings-growth ratio of 4.02 and a beta of 1.21. LeMaitre Vascular has a 52-week low of $21.79 and a 52-week high of $37.35.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Wednesday, November 20th will be issued a dividend of $0.085 per share. The ex-dividend date of this dividend is Tuesday, November 19th. This represents a $0.34 annualized dividend and a dividend yield of 0.96%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.48%.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Featured Story: What are convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.